Clinical Study to Assess the Mode of Action of QBW251 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Condition: Chronic Obstructive Pulmonary Disease
MeSH terms: Lung Diseases; Lung Diseases, Obstructive; Pulmonary Disease, Chronic Obstructive
Intervention: QBW251; Placebo
Intervention description: Capsule 300mg; Capsule 300mg
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Enrollment: 54.0
Sex: All
Minimum age: 40 Years
Healthy volunteers: No

Summary:

      The purpose of this study was to determine whether potentiating the cystic fibrosis
      transmembrane conductance regulator (CFTR) with QBW251 in subjects with COPD would be
      efficacious with regards to reducing lung and systemic inflammation and bacterial
      colonization as potential drivers of airway obstruction, airway destruction, remodeling and
      exacerbations.

      Furthermore, this study provided supportive data to investigate the relationship of COPD
      phenotype and the response in small airway structure, function, mucus load and spirometry
      indices as well as in improvement of overall COPD symptoms and quality of life.
    

Eligibility criteria:

        Inclusion Criteria:

          1. Patients who have signed an Informed Consent Form prior to initiation of any
             study-related procedure.

          2. Male and female adults aged ≥40 years at screening.

          3. Patients with stable COPD, stages GOLD 2-3, according to the current GOLD strategy
             (GOLD 2019) at screening.

             Patients with a post-bronchodilator FEV1/FVC < 0.70 at screening

          4. Patients with airflow limitation indicated by a post-bronchodilator FEV1 ≥ 30% and
             FEV1 < 80% of the predicted normal at Screening who must have had at least 2
             documented moderate or at least 1 documented severe exacerbation(s) between January
             2019 to study screening.

          5. Patients with sputum positive (>0 CFU) for at least one strain of potentially
             pathogenic microorganism at screening (H influenzae, H parainfluenzae, P aeruginosa, S
             pneumoniae, S aureus, Moraxella catarrhalis, Enterobacteriaceae, Stenotrophomonas
             maltophilia, Burkholderia species, and Achromobacter species or any potential
             pathogenic bacteria measured by dilution/outgrowth. Any organism that is to be
             included and that is not included in the list of the protocol defined pathogens will
             be discussed case by case). Sputum samples may be re collected and re-tested once
             during the screening period.

          6. Patients who have been treated with a combination of LABA/LAMA or LABA/ICS or
             LABA/LAMA/ICS at a stable dose for the last 3 months prior to screening.

             COPD patients are allowed to stay on macrolides as background therapy if they have
             bronchiectasis as a secondary diagnosis and if they are treated with them at a stable
             dose 3 months before screening.

          7. Patients with plasma fibrinogen level ≥ 320 mg/dL at screening. Fibrinogen may be
             re-tested once during the screening period.

          8. A COPD Assessment Test (CAT) score of at least 10 at screening.

          9. Current or ex-smokers who have a smoking history of at least 10 pack years (e.g. 10
             pack years = 1 pack/day x 10 years, or 0.5 pack/day x 20 years) at screening.

         10. Patients featuring chronic bronchitis, defined as productive cough that occurs on most
             days (defined as >50% of days) during at least 3 consecutive months in the year prior
             to screening, as assessed by documentation of patient recollection (anamnesis) or
             documented in patients' records.

         11. Able to communicate well with the investigator, to understand and comply with the
             requirements of the study.

        Exclusion Criteria:

          1. Patients with a history of long-QT syndrome or whose QTcF interval at screening
             (Fridericia method) is prolonged (QTcF >450 ms in males, >460 ms in females).

          2. Patients who have a clinically significant* ECG abnormality before randomization.
             Note: Clinically significant abnormalities may include but are not limited to the
             following: left bundle branch block, Wolff-Parkinson-White syndrome, clinically
             significant arrhythmias (e.g., atrial fibrillation, ventricular tachycardia).

          3. Clinical laboratory values abnormalities (including Gamma GT, AST, ALT, total
             bilirubin or creatinine) considered as clinically significant in the opinion of the
             Investigator at screening. For additional guidance on hepatic parameters see exclusion
             criterion #5.

          4. Patients who have clinically significant renal, cardiovascular (such as but not
             limited to unstable ischemic heart disease, NYHA Class III/IV left ventricular
             failure, myocardial infarction), neurological, endocrine, immunological, psychiatric,
             gastrointestinal, or hematological abnormalities, which could interfere with the
             assessment of the efficacy and safety of the study treatment, or patients with
             uncontrolled Type II diabetes.

          5. Patients with a history or current treatment for hepatic disease including but not
             limited to acute hepatitis, cirrhosis or hepatic failure.

               -  Patients with stable chronic hepatitis may be included in the study by agreement
                  with Novartis Medical Expert on a case-by-case basis.

               -  A history of resolved Hepatitis A is not exclusionary.

               -  Patients with prothrombin time international normalized ratio (PT/INR) of more
                  than 1.5xULN at screening. Patients excluded for the PT/INR of more than 1.5xULN
                  can be re-screened when the values have returned to normal.

          6. Patients with a history of malignancy of any organ system, treated or untreated,
             within the past 5 years whether or not there is evidence of local recurrence or
             metastases, with the exception of localized basal cell carcinoma of the skin. Patients
             with a history of cancer and 5 years or more disease free survival time may be
             included in the study by agreement with Novartis Medical Monitor on a case-by-case
             basis.

          7. Patients who develop a COPD exacerbation that required treatment with antibiotics
             and/or oral corticosteroids and/or hospitalization during screening. Re-screening is
             permitted after a minimum of 2 weeks after the resolution of the COPD exacerbation
             (i.e 2 weeks after the stop of SOC therapy for exacerbation).

          8. Patients who have had a respiratory tract infection within 4 weeks prior to screening.
             If a respiratory tract infection occurs during screening, patients can be re-screened
             after a minimum of 2 weeks after resolution of the respiratory tract infection.

          9. Patients with history of asthma or any other clinically relevant lung diseases..

         10. Patients with suspected active pulmonary tuberculosis or currently being treatment for
             active pulmonary tuberculosis.

             Note: Patients with a history of pulmonary tuberculosis can be enrolled if they meet
             the following requirements: history of appropriate drug treatment followed by negative
             imaging results within 12 months prior to screening suggesting low probability of
             recurrent active tuberculosis.

         11. Patients with pulmonary lobectomy, lung volume reduction surgery, bronchoscopic lung
             volume reductions, or lung transplantation.

         12. Patients participating in or planning to participate in the active phase of a
             supervised pulmonary rehabilitation program during the trial. Participation in a
             maintenance program is permitted. Note: the supervised pulmonary rehabilitation
             program as a maintenance program has to be ongoing for at least 3 months at the time
             of enrollment.

         13. Patients with a body mass index (BMI) of more than 40 kg/m2.

         14. Patients receiving any medications in the classes listed in Table 6-5.

         15. Patients receiving any COPD related medications in the classes specified in Table 6-6,
             unless they undergo the required washout period prior to screening and follow the
             adjustment to treatment program.

         16. Patients receiving medications in the classes listed in Table 6-2 should be excluded
             unless the medication has been stabilized for the specified period and the stated
             conditions have been met.

         17. Use of other investigational drugs (approved or unapproved) within 30 days or 5
             half-lives prior to screening, or until the expected pharmacodynamic effect has
             returned to baseline (e.g., biologics), whichever is longer; or longer if required by
             local regulations.

         18. Pregnant or nursing (lactating) women, where pregnancy was defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive human chorionic gonadotropin (hCG) laboratory test.

         19. Women of child-bearing potential, defined as all women physiologically capable of
             becoming pregnant, unless they are using acceptable effective methods of contraception
             during study participation.

         20. Patients who have not achieved an acceptable spirometry result at screening in
             accordance with American Thoracic Society (ATS)/ European Respiratory Society (ERS)
             criteria for acceptability and repeatability.